Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
2.
J Am Coll Nutr ; 23(5): 549S-551S, 2004 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-15466963

RESUMO

OBJECTIVE: The aim of the study was the investigation of plasma magnesium, calcium, copper and zinc and erythrocyte magnesium levels in patients with paranoid schizophrenia and the influence of the therapy with two antipsychotic drugs (haloperidol and risperidone) on these concentrations. METHODS: We investigated the influence of treatment with haloperidol and risperidoneon plasma and erythrocyte magnesium and on plasmatic levels of zinc, calcium and copper on hospitalized 56 patients diagnosed with paranoid schizophrenia (DSM IV). RESULTS: Our data indicate a decrease of erythrocyte magnesium levels in schizophrenic patients (4.82 +/- 3.1 mg/L vs. 59.2 +/- 1.1 mg/L in control group, p < 0.01). The plasma level of magnesium was unchanged (18.9 +/- 2.17 mg/L in schizophrenic patients vs. 18.26 +/- 1.9 mg/L in control group). CONCLUSIONS: We consider plasma Cu(2+)/erythrocyte Mg(2+) and plasma Cu(2+)/Zn(2+) ratio two important biological markers of the acute paranoid schizophrenia.


Assuntos
Antipsicóticos/uso terapêutico , Eritrócitos/química , Magnésio/sangue , Esquizofrenia Paranoide/sangue , Esquizofrenia Paranoide/tratamento farmacológico , Adolescente , Adulto , Idoso , Biomarcadores/sangue , Cálcio/sangue , Cobre/sangue , Feminino , Haloperidol , Humanos , Masculino , Pessoa de Meia-Idade , Risperidona , Espectrofotometria , Zinco/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA